Teva Pharmaceuticals (United States)

Recent papers from Teva Pharmaceuticals (United States)

1. A Practical Review of Technical Barriers and Solutions on Mass Spectrometry-Based Multi-Attribute Method (MAM) in BiotherapeuticsPharmaceuticals · 2026
2. Distribution and target engagement of peripherally administered fremanezumab in the cerebrospinal fluid of healthy volunteersHeadache The Journal of Head and Face Pain · 2026
3. Patient and Healthcare Professional Attitudes and Trial Experiences with a Subcutaneous Long-Acting Injectable Olanzapine (TV-44749) for Schizophrenia TreatmentAdvances in Therapy · 2026
4. Angiotensin-Converting Enzyme in Patients With Early-Stage PsychosisJAMA Psychiatry · 2026
5. Factors associated with rates of long-acting injectable antipsychotic use for schizophrenia: A subgroup analysis of the multinational ADVANCE studyPsychiatry Research · 2026
6. Real-world treatment patterns and outcomes of deutetrabenazine in patients with chorea associated with Huntington disease: A retrospective chart review studyJournal of Huntington s Disease · 2026
7. Fremanezumab for the preventive treatment of migraine in Chinese adults: A Phase 3, randomized controlled trial with an open-label extensionCephalalgia · 2026
8. Tic-Related Functional Impairment Drives the Relationship Between Tics and Depression in Youth With Tourette SyndromeJournal of Child Neurology · 2026
9. Medicinal Chemistry Perspectives on PFAS in Drug Design: Fluorinated Motifs, Innovation, and Patient ImpactJournal of Medicinal Chemistry · 2026
10. Patient Experience With Once-daily Deutetrabenazine Extended-release Tablets for the Treatment of Tardive Dyskinesia in Individuals With Prior Valbenazine Use (P7-16.003)Neurology · 2026
11. Assessment of Dose Proportionality and the Effect of Food on a Once-Daily Extended-Release Tablet Formulation of Deutetrabenazine in Healthy ParticipantsClinical Drug Investigation · 2026
12. A Phase 1 Open-Label Study Assessing the Safety and Pharmacokinetics of TV-46000, an Extended-Release Injectable Suspension of Risperidone for Subcutaneous UseCNS Drugs · 2026
13. Evaluating the Complementary Nature of Randomized Controlled Trials and Real-World Evidence Using Over 5 Years of Experience with Fremanezumab: A Narrative ReviewAdvances in Therapy · 2026
14. Impact of Early Fremanezumab Initiation and Treatment Pauses on the Reduction of Monthly Migraine Days: Analyses from the PEARL Study (P10-15.007)Neurology · 2026
15. Efficacy and Safety of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Children and Adolescents: Outcomes from Two Randomized, Double-blind, Placebo-controlled, Phase 3 Studies (S37.003)Neurology · 2026
16. Treatment with Fremanezumab Attenuates the Association Between Weather and Headache in Participants with Episodic Migraine: A Post Hoc Analysis of the HALO-EM and HALO-LTS Studies (P10-15.004)Neurology · 2026
17. Real-world Use of Deutetrabenazine Reduces Tardive Dyskinesia Severity and Improves Quality of Life: Patient-reported Outcomes in the IMPACT-TD Study (P7-16.004)Neurology · 2026
18. Real-world patient characteristics, treatment patterns, and healthcare resource utilization and costs of tardive dyskinesia in GermanyJournal of Psychiatric Research · 2026
19. Clinical Benefit and Risk Profile of TV-46000 for Patients with Schizophrenia as Assessed by Number Needed to Treat and Number Needed to HarmNeuropsychiatric Disease and Treatment · 2026
20. High-Dose Subcutaneous Administration of Biologics: Overcoming Barriers Through Formulation and Device InnovationAdvanced Drug Delivery Reviews · 2026